Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Is Viking Therapeutics a Millionaire-Maker Stock?
05:20am, Saturday, 27'th Jul 2024
Viking is developing drug candidates in an area of high interest and growth: weight loss. The company is launching a phase 3 clinical trial for its first weight loss candidate.
Pharmaceutical stocks to watch for end of 2024
09:53am, Friday, 26'th Jul 2024
Pharma stocks can be strong investments regardless of economic conditions, as this stability arises because the demand for medications and healthcare services remains steady, even when prices rise.
Why Viking's Weight-Loss Drug News Is Weighing on Eli Lilly, Novo Nordisk Stocks
01:41pm, Thursday, 25'th Jul 2024
Eli Lilly (LLY) and Novo Nordisk (NVO) shares lost ground, while shares of drugmaker Viking Therapeutics (VKTX) soared in intraday trading Thursday after the company reported advances in trials of its
Viking Therapeutics: Pharma Stock Soars on Positive Earnings
12:46pm, Thursday, 25'th Jul 2024
Viking Therapeutics NASDAQ: VKTX is a clinical-stage biopharmaceutical company known for its focus on developing novel treatments for metabolic and endocrine disorders. Viking Therapeutics' earnings r
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
12:25pm, Thursday, 25'th Jul 2024
Viking (VKTX) gains 24% on better-than-expected second-quarter 2024 results, along with encouraging updates regarding its pipeline development plans.
Why Viking Therapeutics Stock Is Skyrocketing Today
12:03pm, Thursday, 25'th Jul 2024
Viking Therapeutics plans to advance its obesity drug VK2735 into late-stage clinical testing. VK2735 could be a formidable rival to Lilly's Zepbound and Novo Nordisk's Wegovy if it's approved.
Viking Therapeutics stock jumps 16% after drugmaker moves weight loss injection to late-stage trial
09:10am, Thursday, 25'th Jul 2024
Shares of Viking Therapeutics jumped on Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected
Viking Therapeutics (VKTX) Stock Pops on Plans to Start Late-Stage Weight Loss Drug Trials
09:09am, Thursday, 25'th Jul 2024
Viking Therapeutics (NASDAQ: VKTX ) stock is heading higher on Thursday as the clinical-stage biopharmaceutical company prepares to start another trial for its weight loss drug. Viking Therapeutics sa
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
06:08am, Thursday, 25'th Jul 2024
Wall Street likes to peer into the fog of the future and guess where a stock is headed. While these stock price predictions are based on educated estimates, often based on information and models unava
Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 24'th Jul 2024
Conference call scheduled for 4:30 p.m. ET today VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24 Oral VK2735 Phase 2 Study in Obesity Expected to Begin 4Q24 Positive
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
12:15pm, Tuesday, 23'rd Jul 2024
Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
09:20am, Monday, 22'nd Jul 2024
Eli Lilly is having great success in the market for weight loss treatments. Viking is working on a candidate that could potentially outperform Eli Lilly's.
Viking Therapeutics: Great Clinical Results Do Not Guarantee Commercialization Success
09:20am, Saturday, 20'th Jul 2024
VKTX's obesity therapy candidate, VK2735, demonstrates accelerated weight loss results compared to Wegovy/ Mounjaro and the next-gen candidates, including CagriSema/ Zepbound/ Retatrutide. This explai
3 Monster Stocks in the Making to Buy Right Now
06:00am, Saturday, 20'th Jul 2024
CRISPR Therapeutics now has its first product on the market. Zealand Pharma has two promising candidates targeting the huge obesity and MASH/NASH markets.
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
10:56am, Friday, 19'th Jul 2024
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.
